首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   414篇
  国内免费   16篇
  完全免费   54篇
  综合类   484篇
  2017年   10篇
  2016年   15篇
  2015年   12篇
  2014年   21篇
  2013年   29篇
  2012年   58篇
  2011年   69篇
  2010年   52篇
  2009年   35篇
  2008年   43篇
  2007年   51篇
  2006年   9篇
  2005年   7篇
  2004年   5篇
  2003年   1篇
  2002年   2篇
  2000年   6篇
  1999年   2篇
  1998年   2篇
  1997年   11篇
  1996年   9篇
  1995年   13篇
  1994年   5篇
  1993年   2篇
  1992年   4篇
  1991年   1篇
  1989年   5篇
  1987年   3篇
  1986年   2篇
排序方式: 共有484条查询结果,搜索用时 46 毫秒
1.
重症下肢缺血的血管腔内治疗   总被引:12,自引:0,他引:12  
目的评价血管腔内治疗下肢动脉硬化闭塞症重症下肢缺血的临床效果。方法2005年4月-2006年5月采用血管腔内治疗重症下肢缺血24例共29条肢体,主要临床症状均为静息痛,其中合并溃疡或肢端坏疽12例(50%)。本组29条肢体均接受血管腔内治疗,其中有4条肢体行单纯球囊扩张,4条肢体术中同时行股胭动脉人工血管旁路术联合膝下胭胫动脉血管腔内球囊扩张成形术,21条肢体行支架植入。结果股胭动脉球囊扩张和支架植入技术成功率为100%,膝下动脉球囊扩张成功率为88%,术后患者临床症状明显好转,静息痛消失,溃疡愈合。围手术期膝下截肢1例,截肢率为3.4%。结论血管腔内治疗下肢动脉硬化闭塞症重症下肢缺血是一种安全有效的治疗方法。  相似文献
2.
目的 研究静脉应用重组人脑利钠肽(rhBNP)对急性心肌梗死经皮冠状动脉介入治疗(PCI)术后患者心室重塑和左心功能的影响。方法 选择48例发病12h内的急性前壁心肌梗死PCI术后患者,随机分为rhBNP组25例和常规治疗组23例,分别于发病后1周、4周和24周采用二维超声心动图测定舒张末期容积指数(LVEDVI)、收缩末期容积指数(LVESVI)、左室射血分数(LVEF)、左室质量指数(LVMI),计算梗死区的局部室壁运动指数(RWMI)。结果 两组患者治疗1周时LVEDVI、LVESVI、LVEF、RWMI、LVMI间差异均无显著性意义(P〉0.05);治疗4、24周时LVEDVI、LVESVI、LVEF以及治疗24周时RWMI、LVMI间差异均有显著性意义(P〈0.05)。结论 PCI术后在常规治疗的基础上应用rhBNP可进一步阻抑急性前壁心肌梗死后心室重塑,改善左心功能。  相似文献
3.
目的初步尝试机器人单孔腹腔镜下行猪肾部分切除术及肾盂输尿管成形术,评估机器人单孔腹腔镜下行泌尿外科重建手术的可行性和不同通道技术的人机工程学效果,总结操作经验。方法猪肾部分切除术:完全侧卧位,平脐水平,沿腹直肌外缘切开4 cm长皮肤切口,钝性分离皮下脂肪,以气腹针建立气腹。按菱形将4个套管置入腹腔,其中左右为8mm的达芬奇机器人金属套管,上下为Surgiquest 10 mm无阀套管。安装机器人臂后,按常规完成肾部分切除术,肾脏缺损采用"滑夹"的无结技术进行全层水平褥式缝合关闭。肾盂输尿管成形术(UPJ):改用Surgiquest新型无阀单孔通道,切口两侧置入8 mm的机器人金属套管。观察镜接12 mm普通腹腔镜套管后,置入单孔通道内,按常规完成UPJ成形术。结果完成肾部分切除术2例,通道建立时间分别为5、8 min,机器人系统安装时间为11、9 min,手术操作时间为55、42 min,温缺血时间23、18min,出血50、20 ml。完成肾盂输尿管成形术2例,通道建立时间为17、12 min,机器人安装时间为5、4 min,手术操作时间为32、25 min,出血均为0 ml。结论机器人单孔腹腔镜手术在合理安置通道后,能顺利完成泌尿外科高难度重建手术;专用机器人单孔通道可获得更理想的人机工程学效果。  相似文献
4.
糖尿病下肢血管病变介入治疗初步探讨   总被引:6,自引:0,他引:6  
Zhuang BX  Ma LB  Yu CL  Zhang T  Yang M  Shi B  Shi DZ 《中华医学杂志》2007,87(26):1821-1824
目的对糖尿病下肢血管病变介入治疗技术进行分析并观察近期疗效。方法回顾性分析2005年8月至2007年2月期间收治的Fontaine分级Ⅰ-Ⅳ级糖尿病下肢病变患者150例(176条患肢),采用球囊扩张治疗为主。观察手术成功率、并发症、临床疗效、踝/肱指数(ABI)、治疗血管再狭窄等。结果150例患者(176条患肢)共进行187次介入治疗,161条患肢治疗成功,手术成功率为91.4%,无严重并发症。患者手术后临床症状均明显改善。术前所有患者ABI为0.34±0.27,术后ABI为0.96±0.24。共有134例患者(153条患肢)经术后随访,平均随访5个月(1~16个月),术后1、6个月ABI比值分别为0.88±0.34、0.71±0.26;超声检查示术后随访期间有21例(13.7%)治疗血管再狭窄或闭塞,其中11例(7.2%)再次行介入治疗。结论糖尿病下肢动脉病变行介入治疗手术技术成功率较高、并发症较低、疗效确切,可作为糖尿病下肢动脉病变的首选治疗。  相似文献
5.
目的探讨急性ST段抬高型心肌梗死(STEMI)患者急诊经皮冠状动脉介入治疗(PCI)时冠状动脉(冠脉)内注射负荷剂量盐酸替罗非班对心肌灌注及心功能的影响。方法选择2007年7月—2008年12月我科确诊STEMI并接受急诊PCI患者70例,随机分为观察组(36例)和对照组(34例)。两组患者均进行PCI,术中观察组患者给予盐酸替罗非班10μg/kg冠脉内注射,对照组给予等量0.9%氯化钠注射液冠脉内注射。比较两组患者PCI术后即刻造影结果,术后7、30、180 d的左室射血分数(EF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)及术后180 d主要不良心血管事件(MACE)发生率,同时观察住院期间的出血并发症。结果观察组患者术后校正TIMI帧数、术后2 h ST段回落程度、磷酸肌酸激酶同工酶(CK-MB)峰值及峰值时间均优于对照组,差异有统计学意义(P〈0.05);梗死相关血管无复流发生率及术后180 d MACE(包括死亡、再梗死、再次靶血管重建)发生率显著低于对照组,差异有统计学意义(P〈0.05);与对照组比较,观察组术后7、30、180 d的EF显著增加,LVEDD、LVESD显著降低,差异有统计学意义(P〈0.05)。两组住院期间出血并发症的发生率间差异无统计学意义(P〉0.05)。结论对于STEMI患者行急诊PCI术中联合冠脉内注射替罗非班治疗可减少无复流、慢血流现象的发生,改善心肌水平再灌注状态和左室功能,同时不增加出血发生率,有利于提高临床预后。  相似文献
6.
Background We developed a new combined strategy of thrombus aspiration plus intra-infarct-related artery (IRA) bolus administration of tirofiban via the aspiration catheter in patients with ST-segment elevation myocardial infarction (STEMI). This strategy can reduce the distal embolism and achieve highly localized concentrations of tirofiban, which can improve myocardial reperfusion without increasing the risk of bleeding. The aim of this study was to investigate whether this combined strategy is superior to thrombus aspiration alone in improving myocardial perfusion in patients with STEMI undergoing primary angioplasty.Results Baseline characteristics of the two groups were well-balanced. The TIMI 3 flow showed a better tendency in the intra-IRA group than in the aspiration alone group (97.22% vs. 87.04%, X2=7.863, P=0.049). The peak of CK-MB (83.9 (68.9-310.5) U/L vs. 126.1 (74.7-356.7) U/L, P=0.034) and Tnl (42.7 (14.7-113.9) ng/ml vs. 72.5 (59.8-135.3) ng/ml, FMD.029) were lower in the intra-IRA group than in the aspiration alone group. LVEF in the hospital favored the intra-IRA group, (45.7±8.3)% to (42.9±12.1)%, t=1.98, P=0.049. There was a tendency towards a lower MACE at 9-month follow-up in the intra-IRA group although it did not reach statistical difference (Log-rank X2=2.865, P=0.09). There was no statistical difference in any bleeding events between the two groups.Conclusions Thrombus aspiration plus intra-IRA bolus administration of tirofiban combined with angioplasty may be related with improved myocardium perfusion, saved more myocardium, and resulted in a better clinical prognosis.  相似文献
7.
Background Current guidelines support primary percutaneous coronary intervention (primary PCI) as the first treatment of choice (as opposed to thrombolytic therapy) for patients with acute ST-segment elevation myocardial infarction (STEMI) especially when delivered within 12 hours of symptom onset. We aimed to evaluate the impact of different clinical pathways on reduction of reperfusion delay and subsequent improvement in outcomes in patients with STEMI. Methods From November 2005 to November 2007, 546 consecutive patients with definite STEMI, who upon arrival at the emergency room were triaged to undergo primary PCI, were included. Of them, 271 patients were brought directly to catheterization laboratory (rapid group), and 275 patients were admitted to the coronary care unit (CCU) or cardiac ward first, and then transferred to the catheterization laboratory (non-rapid group). Primary endpoint was door-to-balloon (D2B) time, and secondary endpoints included infarct size assessed by peak CK-MB level and rates of major cardiac adverse events (MACE) including death, reinfarction, or target-vessel revascularization during hospitalization and at 30-day clinical follow-up.
Results Baseline clinical characteristics, angiographic features and procedural success rates were comparable between the two groups, except that more patients received glycoprotein lib/Ilia receptor inhibitors before angiography (84.0% and 77.1, P=0.042) and had TIMI 3 flow in the culprit vessel at initial angiogram (17.1% and 9.2%, P=0.007) in the non-rapid group. The D2B time was shortened ((108±44) minutes and (138±31) minutes, P 〈0.0001), and number of patients with D2B time 〈90 minutes was greater (22.6% and 10.9%, P 〈0.0001) in the rapid group. The advantages associated with rapid intra-hospital transfer were enhanced if the patients presented to the hospital at regular hours. Peak CK-MB level was significantly reduced in the rapid group. In-hospital mortality (4.1% and 5.8%) and cumulative MACE rate (7.0% and 9.8%) did not significantly differ between rapid and non-rapid groups. At 30 days, cumulative death- and MACE-free survival rates were improved in the rapid group (94.5% and 89.5%, P=0.035; 90.1% and 84.0%, P=0.034, respectively).
Conclusions Clinical pathway with bypass of CCU/cardiac ward admission was associated with rapid reperfusion, smaller infarct size, and improved short-term survival for patients with STEMI undergoing primary PCI. In the future, it is essential to reduce the time delay for patients presenting at off-hours.  相似文献
8.
Background There are limited data on the efficacy of drug-eluting stents (DES) for treatment of chronic total occlusions (CTO). The aim of the study was to evaluate the long-term clinical outcomes of DES implantation for CTO compared with bare-metal stent (BMS) implantation.
Methods Between June 1995 and December 2006, a total of 1184 patients with successful recanalization of at least one de novo CTO lesion were consecutively registered, including 660 (55.7%) who underwent DES and 524 (44.3%) who underwent BMS implantation. All patients were followed up for up to 5 years for occurrence of major adverse cardiac events (MACE). Long-term survival rates were estimated with the Kaplan-Meier method.
Results Baseline clinical and angiographic characteristics were comparable between the two groups except that patients in the DES group received longer dual antiplatelet therapy ((7.4±2.5) months vs (1.7±0.8) months, P 〈0.001). Average follow-up periods were (4.7±0.89) and (3.2±1.3) years for the BMS and DES groups, respectively. There was no significant difference in 5-year survival rates between the two groups (90.3% for DES group vs 89.6% for BMS group, Log-rank P=0.38), but the 5-year target vessel revascularization (TVR)-free survival rate in the DES group was significantly higher than that in the BMS group (81.6% vs 73.5%, Log-rank P 〈0.001). The cumulative MACE-free survival in the DES group was also significantly higher than that in the BMS group (80.6% vs 71.5%, Log-rank P〈0.001). The rates of readmission caused by cardiovascular disease (27.0% vs 37.8%, P 〈0.001) and the need for bypass surgery were significantly lower in the DES group (1.5% vs 3.4%, P 〈0.05). By multivariable analysis, DES implantation could significantly lower the long-term MACE risk of PCI for CTO patients (HR: 0.492; 95% Cl 0.396-0.656, P 〈0.001). Left ventricular ejection fraction 〈50% and elderly (〉65 years) were identified as independent predictors of long-term MACE during follow-up.
Conclusion This study demonstrates the long-term (up to 5 years) efficacy of DES for treatment of CTO, which is superior to BMS implantation in reducing the rates of TVR and MACE, as well as the need of re-admission and bypass surgery.  相似文献
9.
症状性颅内动脉粥样硬化性狭窄的支架成形术   总被引:3,自引:0,他引:3       下载免费PDF全文
颅内动脉粥样硬化是缺血性卒中的重要原因之一,占所有缺血性卒中的8%~10%。尽管采用抗栓治疗或搭桥手术治疗,症状性颅内动脉粥样硬化患者的预后仍然不佳。颅内支架成形术可能是有前景的治疗方法。本文就颅内支架成形术治疗症状性颅内动脉粥样硬化性狭窄的发展过程、最新的临床进展和有关概念进行讨论。  相似文献
10.

Background  Myocardial tissue-level perfusion failure is associated with adverse outcomes following ST-elevation myocardial infarction (STEMI) despite successful epicardial recanalization. We have developed a new quantitative index—thrombolysis in myocardial infarction (TIMI) myocardial perfusion frame count (TMPFC)—for assessing myocardial tissue level perfusion. However, factors affecting this novel index of myocardial perfusion are currently unknown.

Methods  A total of 255 consecutive STEMI patients undergoing primary angioplasty were enrolled. Myocardial tissue level perfusion was assessed by TMPFC, which measures the filling and clearance of contrast in the myocardium using cine-angiographic frame counting. We differentiate three groups with two cut off values for TMPFC: a TMPFC of 90 frames was the upper boundary of the 95% confidence interval (CI) for the TMPFC observed in normal arteries, and a TMPFC of 130 was the 75th percentile of TMPFC.

Results  STEMI patients with TMPFC >130 frames (68 patients, 26.7%) had higher clinical and angiographic risk factor profiles as well as a higher 30-day MACE rate compared with those with TMPFC ≤90 frames and those with TMPFC >90 and ≤130 frames. Multivariable analysis identified that the independent predictors of TMPFC >130 frames were age ≥75 years (OR 2.08, 95% CI 1.21 to 3.58, P=0.007), diabetes (OR 1.37, 95% CI 1.01 to 1.86, P=0.042), Killip class ≥2 (OR 1.52, 95% CI 1.05 to 2.21, P=0.027), and prolonged pain-to-balloon time (OR 1.73, 95% CI 1.07 to 2.79, P=0.013). TMPFC >130 frames was identified as the strongest independent predictor of 30-day major adverse cardiac event (MACE) (OR 2.77, 95% CI 1.21 to 6.31, P=0.008), along with age ≥75 years (OR 2.19, 95% CI 1.11 to 4.33, P=0.016), female gender (OR 1.67, 95% CI 1.03 to 2.70, P=0.038), and Killip class ≥2 (OR 1.83, 95% CI 1.07 to 3.14, P=0.021).

Conclusions  STEMI patients with poor myocardial perfusion assessed by TMPFC had higher risk factor profiles. Advanced age, diabetes, higher Killip class, and longer ischemia time were independent predictors of impaired TMPFC after primary percutaneous coronary intervention. These results emphasize that particular attention should be paid on myocardial microvascular reperfusion in STEMI patients with these risk factors.

  相似文献
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号